Equities research analysts expect ImmunoGen, Inc. (NASDAQ:IMGN) to announce sales of $23.69 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for ImmunoGen’s earnings. The highest sales estimate is $37.95 million and the lowest is $8.30 million. ImmunoGen reported sales of $7.66 million during the same quarter last year, which would suggest a positive year over year growth rate of 209.3%. The business is scheduled to announce its next quarterly earnings report on Friday, October 27th.

According to Zacks, analysts expect that ImmunoGen will report full year sales of $23.69 million for the current financial year, with estimates ranging from $115.10 million to $130.65 million. For the next fiscal year, analysts forecast that the company will report sales of $64.92 million per share, with estimates ranging from $51.60 million to $85.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for ImmunoGen.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The firm had revenue of $39.02 million during the quarter, compared to analyst estimates of $30.59 million. During the same period last year, the firm earned ($0.53) EPS. ImmunoGen’s quarterly revenue was up 426.6% on a year-over-year basis.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of ImmunoGen from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Royal Bank Of Canada raised shares of ImmunoGen from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $5.00 to $12.00 in a research note on Thursday, July 6th. Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the stock a “hold” rating in a research note on Friday, July 28th. Jefferies Group LLC reissued a “buy” rating and set a $6.00 target price on shares of ImmunoGen in a research note on Wednesday, June 28th. Finally, William Blair reissued an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $7.72.

ImmunoGen (IMGN) opened at 5.72 on Tuesday. The firm’s market cap is $512.49 million. The stock has a 50 day moving average of $6.39 and a 200 day moving average of $4.47. ImmunoGen has a one year low of $1.51 and a one year high of $8.04.

A number of large investors have recently bought and sold shares of IMGN. Envestnet Asset Management Inc. increased its stake in ImmunoGen by 2.8% in the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 743 shares during the period. Gould Asset Management LLC CA bought a new stake in ImmunoGen during the second quarter valued at $107,000. Acadian Asset Management LLC bought a new stake in ImmunoGen during the first quarter valued at $117,000. Aperio Group LLC increased its stake in ImmunoGen by 45.1% in the second quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 5,221 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in ImmunoGen by 7.7% in the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 2,753 shares during the period. 74.69% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $23.69 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/15/zacks-brokerages-anticipate-immunogen-inc-imgn-will-announce-quarterly-sales-of-23-69-million.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Get a free copy of the Zacks research report on ImmunoGen (IMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.